Analgesic Efficacy and Safety of IV Nalbuphine Versus IV Butorphanol in patients undergoing Tympanoplasty
Not Applicable
Completed
- Conditions
- Health Condition 1: H729- Unspecified perforation of tympanic membrane
- Registration Number
- CTRI/2020/08/027482
- Lead Sponsor
- Dr Shruti Hazari
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 120
Inclusion Criteria
Patients giving consent
Patients undergoing elective Tympanoplasty surgery
Patients under ASA 1 and ASA2
Exclusion Criteria
Patient refusal
Patients ASA 3 or more
Patients on opioid or sedatives
Alcohol intake
Hypersensitivity reaction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the opioid receptor interaction mechanisms of IV Nalbuphine and IV Butorphanol in post-Tympanoplasty pain management?
How does IV Nalbuphine's analgesic efficacy compare to IV Butorphanol as standard-of-care for tympanic membrane perforation patients?
Are there genetic or metabolic biomarkers predicting response to IV Nalbuphine or IV Butorphanol in postoperative otologic pain?
What adverse event profiles and management strategies differentiate IV Nalbuphine from IV Butorphanol in Tympanoplasty patients?
What combination therapies with non-opioid adjuvants enhance analgesic efficacy of IV Nalbuphine or IV Butorphanol in otologic surgery?